Publications found:
73,128
Sort by:
Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)
US$ 800.00
... Scope of the report The report titled “Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)” provides an in-depth analysis of global rheumatoid arthritis market with special focus on biologics drugs. It also accesses the key opportunities and underlying trends in the market and outlines the ...
November 2013
64 pages
Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)
US$ 700.00
... report titled “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)“ provide an insight into the market dynamics and various trends and opportunities associated with the global multiple sclerosis market. The report ... contributor to the global multiple sclerosis market has been assessed. The report concludes with a brief discussion of major factors driving the global multiple sclerosis market and profiles major ...
November 2013
54 pages
Global Age-Related Macular Degeneration (AMD) Market: Trends and Opportunities (2013-2018)
US$ 800.00
... Report The report titled “Global Age-Related Macular Degeneration (AMD) Market: Trends & Opportunities (2013-2018)” provides an in-depth analysis of the global age-related macular degeneration market with detailed analysis of various ... Age-related macular degeneration (AMD) is a condition affecting older people, and involves the loss of the person's central field of vision. Several forms of AMD exist such as early AMD ...
November 2013
70 pages
Sports Medicine Market Report: 2013 Edition
US$ 800.00
... sports medicine market, the report also analyzes the global orthopedics market and global arthroscopic market. The report elicits the intricacies of market size, factors influencing market ... expense. The report also provides company profiles of the key players in the global sports medicine market along with a ...
October 2013
48 pages
Coronary Stents Market in India 2013
US$ 950.00
... after order is placed. Netscribes’ latest market research report titled Coronary stents Market in India 2013 states that manufacturers of coronary stents are experiencing high demand for their ... form of a much needed regulatory mechanism and will benefit the coronary stents market as well.
October 2013
134 pages
Market Access Collection
US$ 4,095.00
The collection includes the following reports: Market Access Canada Market Access in the EU5 – a comparative overview Value-based Key Account Management and the NHS – ensuring optimal performance under new rules Biosimilars in Emerging Markets
October 2013
-
Marketing Collection
US$ 6,495.00
The collection includes the following reports: Pharma and Gamification: motivating positive outcomes – a primer The Impact of Mobile Health on Patient-Centric ... real-world commercial benefit from closed-loop marketing Driving Brand Value in Emerging Markets - winning strategies and tactics Big Data ...
October 2013
-
Medical Affairs Collection
US$ 2,295.00
The collection includes the following reports: MSL-KOL Engagement: delivering value under new rules Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value The Path to Product Inclusion in Clinical Guidelines: Strategies for Success ...
October 2013
-
Emerging Markets Collection
US$ 3,295.00
The collection includes the following reports: Inside China’s Pharma Sales Force – insights from the frontline Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets Driving Brand Value in Emerging Markets - winning strategies and tactics
October 2013
-
Regeneron - Eylea’s Growth Potential and Pipeline is Lucrative Enough!
US$ 140.00
... of Eylea (aflibercept, VEGF-Trap Eye, L, wet-AMD, Central Retinal Vein Occlusion – CRVO, partnered with Bayer for ex-US) in Diabetic Macular Edema (DME) and myopic choroidal neovascularization (mCNV) and promise of the late-stage pipeline esp. anti-PCSK9 mAb, Alirocumab (REGN727, PhIII, Hypercholesterolemia ...
October 2013
7 pages
Thailand Medical Tourism Market (Spending) Analysis & Forecast
US$ 1,290.00
... report titled 'Thailand Medical Tourism Market (Spending) Analysis & Forecast' provides a comprehensive analysis of the Thailand medical tourism market covering in detail ... . All the 15 countries in the report have been studied from 2 viewpoints. Medical Tourists Visits in Thailand from the year 2001-2018 ...
October 2013
112 pages
ABLYNX - Nanobodies - Turnarond on the Horizon!
US$ 140.00
... of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX ... ) and its nanobody platform’s’ potential in the limelight! Though ABLX suffered from several setbacks in 2011, ...
October 2013
7 pages
Merck Update: HCV combo, Lambrolizumab and Corporate Restructuring Program
US$ 90.00
Merck announced restructuring (cost efficiency) program which is likely to ... by 2015) announced by the Company through workforce reduction across all functional divisions, head quarter relocation, out ... . More focused attention on therapy areas where Merck has proven its abilities irrespective of unmet need ...
October 2013
3 pages
Global Oncolytic Virus Therapy Pipeline Analysis
US$ 1,500.00
... survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the ... selective without the need for any genetic manipulation. “Global Oncolytic Virus Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
October 2013
105 pages
Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
US$ 7,495.00
The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains ... , products, late-stage pipeline drugs, product positioning, in the context of COPD market trends. Event Bulletins Benefit from the latest KOL ...
October 2013
157 pages
Physician Views: Life beyond statins – what opportunity for PCSK9 inhibitors?
US$ 695.00
... demonstrated when administered in combination with statin therapy. Given the entrenchment (and genericisation) of most statin therapies, coupled with the subcutaneous ... potential for the emergent PCSK9 inhibitor class. This week's Physician Views poll asks US and 5EU-based cardiologists and general ...
October 2013
-
Physician Views: The great generic Advair opportunity – a physician perspective
US$ 695.00
... the second pharmacy benefits manager to do so (after CVS Caremark) - see Physician Views Poll Results – US Pulmonologists keen for Breo Ellipta – can payers ... device. This week's Physician Views poll asks pulmonologists and general practitioners based in the US and 5EU markets (where a substitutable generic version of Advair ...
October 2013
-
Global Testosterone Therapy Market: Trends and Opportunities (2013-2018)
US$ 750.00
... report titled “Global Testosterone Therapy Market”: Trends & Opportunities (2013-2018)” provides an in-depth analysis of the global Testosterone Therapy market with detailed analysis of symptoms, diagnosis and treatment of testosterone deficiency. The report majorly focuses on the US testosterone therapy market and also assesses ...
October 2013
60 pages
Strategies for Working With Real World Data
US$ 395.00
... that is, increasingly, transforming healthcare into ‘reality medicine’ that responds to the real world use of medicines rather than that prescribed by randomised controlled ... to pricing and positioning. How should pharma respond? In Strategies for Working with Real World Data, FirstWord makes a strong case for ...
October 2013
61 pages
Global Hemophilia Market Report: 2013 Edition
US$ 800.00
... new patient registration. The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large ...
September 2013
56 pages
MEDIVIR - Simeprevir- Good with and without IFN Combinations!
US$ 140.00
... Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir ... Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR ...
September 2013
3 pages
Private Healthcare Market in Kannur 2013
US$ 950.00
... is placed. Netscribes’ latest market research report titled Private Healthcare Market in Kannur 2013 identifies the healthcare scenario in Kannur. The healthcare landscape in Kannur is dotted with both private and public hospitals ...
September 2013
63 pages
Private Healthcare Market in Perinthalmanna 2013
US$ 950.00
... days after order is placed. Netscribes’ latest market research report titled Private Healthcare Market in Perinthalmanna 2013 identifies the healthcare scenario in Perinthalmanna. Perinthalmanna is a city and a municipality in Malappuram district ...
September 2013
38 pages
Telemedicine and M-Health Convergence Market
US$ 3,800.00
... Research announces that it has published a new study Telemedicine and M-Health Market Convergence Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. ... , but this time in a more effective manner, on that is supported by technology. Telemedicine systems come from IBM, Intel, Honeywell, Vitarian, and Bosch ...
September 2013
879 pages
Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN
US$ 250.00
Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...
September 2013
7 pages
Consensus Outlook: Multiple Sclerosis
US$ 7,495.00
Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary ... efficacious therapy, and continued uptake of existing therapies. Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and ...
September 2013
35 pages
US Proton Therapy Outlook 2017
US$ 2,000.00
... to make it more accessible to patients. According to the “US Proton Therapy Outlook 2017” by RNCOS, the United States will be home to almost 27 such centers ... will breach the Billion dollar mark to attain revenue of US$ 1.17 Billion by 2017. The following 65 pages report provides an insight into the cancer ...
September 2013
65 pages
Competitor Analysis: Smallpox Vaccines & Therapeutics
US$ 199.00
The Competitive Intelligence report Smallpox Vaccines & Therapeutics as of August 2013 provides a competitor analysis in the development pipelines of novel vaccines and therapeutics for prophylaxis of Variola virus infection and treatment of smallpox. Purchase of the pdf report includes a 6-month online ...
August 2013
20 pages
Novartis, 2013 Outlook revised but below expectations
US$ 90.00
Novartis reported strong 2Q-2013 financial results due to the absence of Diovan generics in the US. For the same reason, Novartis has revised ... its earning guidance for the full year 2013. It ... low-single digit rate. We see the revision in guidance as inadequate and not reflective of ...
August 2013
3 pages
Healthcare IT Outsourcing Market - By Application [Provider (EHR, RCM, LIMS) Payer (CRM, Claims Management, Fraud Detection, Billing) Life Science (ERP, CTMS, CDMS) Operational (SCM, BPM) & Infrastructure (IMS, Cloud Computing)] & Industry - Global Forecast To 2018
US$ 3,390.00
... outsourced. The healthcare IT outsourcing market for this report has been segmented by application and by industry. The application market is further classified as provider IT outsourcing, payer IT outsourcing, life science IT outsourcing, operational IT outsourcing ...
August 2013
204 pages
Merck – One timers and Forex weigh on Merck’s guidance
US$ 90.00
MRK reported its 2Q 2013 results: the net sales decline by 11% ($11.0b) including negative foreign exchange impact by 3% compared to last year. Company reiterated its 2013 non-GAAP EPS guidance ($3.45 and $3.55) while revised its GAAP EPS to be between $1.84 and $2.05 (previous $1.92-2.16). MRK expects its ...
August 2013
1 pages
The Impact of Mobile Health on Patient-Centric Disease Management
US$ 595.00
... trials. Through The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores the emerging and exciting world of mobile and digital health apps. Based ... , Boehringer Ingelheim. The Impact of Mobile Health on Patient-Centric Disease Management answers key questions: How can pharma harness the mobile and digital app ...
August 2013
105 pages
Market Access in the EU5 – a comparative overview
US$ 595.00
... . For the Pharma industry it’s tight, and it’s getting tighter. Essential market access data and insights are now available in this new report ... , Market Access in the EU5 – a comparative overview, provides a detailed snapshot of the current environment and trends that are influencing market access in the five leading EU markets: France ...
August 2013
107 pages
